Johns Hopkins Center for Psychedelic & Consciousness Research

The Johns Hopkins Center for Psychedelic & Consciousness Research was established in 2019 as a dedicated research facility within the Johns Hopkins School of Medicine. The center conducts rigorous clinical trials investigating the therapeutic potential of psychedelic compounds, particularly psilocybin and MDMA, for treating conditions including depression, anxiety, addiction, and end-of-life distress. Led by Roland Griffiths and Matthew Johnson, the center has become one of the most prominent institutions in the modern psychedelic research renaissance, combining neuroscience, psychology, and clinical medicine.

The center's work has significantly influenced the regulatory landscape and public perception of psychedelics, demonstrating safety and efficacy in controlled therapeutic settings. Their research has contributed to FDA breakthrough therapy designations for psilocybin-assisted therapy and MDMA-assisted therapy, accelerating the path toward clinical approval. The center also investigates the mechanisms of consciousness and the subjective experiences induced by psychedelics, bridging neuroscience and phenomenology.